Jana G Hashash
Overview
Explore the profile of Jana G Hashash including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
200
Citations
1671
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu R, Hashash J, Stocchi L
Expert Rev Gastroenterol Hepatol
. 2025 Jan;
19(2):131-144.
PMID: 39889271
Introduction: Crohn's disease (CD)-related abdominal abscesses require tailored management strategies taking into consideration the variability in abscess size, location, and underlying CD activity. Areas Covered: This review discusses current approaches...
2.
Caldera F, Kane S, Long M, Hashash J
Clin Gastroenterol Hepatol
. 2025 Jan;
PMID: 39800200
Description: The aim of this American Gastroenterological Association (AGA) Clinical Practice Update (CPU) is to provide Best Practice Advice statements for gastroenterologists and other healthcare providers who provide care to...
3.
Odah T, Karime C, Hashash J, Kinnucan J, Picco M, Farraye F
J Clin Gastroenterol
. 2024 Dec;
PMID: 39729973
Background: Video capsule retention is a complication that can have serious consequences in patients with Crohn's disease (CD). The patency capsule was developed to detect small bowel strictures. The usefulness...
4.
Alsakarneh S, Jaber F, Parajuli S, Abboud Y, Abuelazm M, Hashash J
Am J Ther
. 2024 Dec;
PMID: 39670629
No abstract available.
5.
Vora H, Ibrahim R, Chan J, Farraye F, Hashash J
Ann Gastroenterol
. 2024 Nov;
37(6):695-698.
PMID: 39568714
Background: The terminal ileum is typically examined during colonoscopies, especially in patients with inflammatory bowel disease (IBD) and diarrhea. The yield from performing biopsies of endoscopically normal appearing terminal ileum...
6.
Kochhar G, Khataniar H, Hashash J, Tabaku F, Regueiro M, Farraye F, et al.
Inflamm Bowel Dis
. 2024 Oct;
PMID: 39478367
Introduction: There is limited real-world evidence comparing the effectiveness of ozanimod to vedolizumab as first-line advanced therapies in patients with ulcerative colitis (UC). Methods: We conducted a retrospective cohort study...
7.
Alsakarneh S, Hashash J, Farraye F, Ghoz H
Am J Gastroenterol
. 2024 Oct;
120(3):682.
PMID: 39445698
No abstract available.
8.
Kilani Y, Alsakarneh S, Aldiabat M, Ferreira M, Mosquera D, Jaber F, et al.
Gastro Hep Adv
. 2024 Sep;
3(7):1001-1004.
PMID: 39309368
No abstract available.
9.
Odah T, Karime C, Desai A, Picco M, Kinnucan J, Hashash J, et al.
Dig Dis Sci
. 2024 Sep;
69(10):3911-3919.
PMID: 39251560
Background And Aims: Upadacitinib is an oral selective Janus kinase (JAK) inhibitor approved in the United States for ulcerative colitis (UC) and Crohn's disease (CD). However, data regarding its use...
10.
Alsakarneh S, Ahmed M, Jaber F, Abuassi M, Mourad F, Francis F, et al.
Ann Gastroenterol
. 2024 Sep;
37(5):527-535.
PMID: 39238799
Background: The epidemiology of inflammatory bowel disease (IBD) has changed rapidly in recent years. Objective data concerning the IBD burden in the Middle East and North Africa (MENA) region is...